All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the ...

Anthropic has launched a new research effort focused on the biggest societal challenges posed by more powerful AI systems. The institute will study how advanced AI could affect the economy, the legal ...

FDA clearance advances phase 2b evaluation of teverelix in advanced prostate cancer patients where ADT choice is constrained by high baseline cardiovascular risk. Trial design targets rapid, durable ...

The Company is developing Teverelix® as a best-in-class market product for advanced prostate cancer patients with high CV risk and a first in class product for Acute Urinary Retention Relapse ...

Immunotherapy targeting the programmed cell death (ligand)-1 (PD-[L]1) pathway has improved outcomes in patients with advanced/metastatic non-small cell lung cancer (NSCLC) without actionable genomic ...

Dr. Andrew Pieper, director of the Brain Health Medicines Center at University Hospitals and senior author of the study, emphasizes this represents a fundamental shift in understanding the disease.

An illustration representing the importance of email deliverability in banking and finance. The image emphasizes how businesses can face risks from undelivered emails, impacting customer trust and ...

The legislature is poised to send a bill to Gov. Phil Murphy that would direct a state regulatory agency to study the feasibility of building advanced nuclear reactors in the state. The bill, S4689, ...

When you think of time perception, bees probably aren’t the first creatures that come to mind. Yet a new study suggests these tiny insects may have a surprisingly sophisticated sense of timing that ...

Radiotherapy benefits are most pronounced in patients with fewer than five bone metastases, improving progression-free survival and 5-year survival rates. Across all patients, radiotherapy ...

Objective This study defined a retrospective cohort of patients in England with primary advanced or recurrent (A/R) endometrial cancer (EC) who may have been eligible for clinical trials evaluating ...